Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EURONET WORLDWIDE, INC.EEFT · Entity 4336 | Director · CEO & President | February 26, 2026 | March 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EURONET WORLDWIDE, INC.
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.02 per shareSEC Table I · non-derivative | Direct | 1,450,716 |
Ending reported balance
After 2026-02-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-26 · Grant · Acquired 54,949 · Balance 1,475,133 F1: Vesting of shares from performance-based stock awards granted on December 7, 2021 (3,935), December 6, 2022 (40,345), December 12, 2023 (5,675) and December 10, 2024 (4,994). Row 2 · 2026-02-26 · Tax withholding · Disposed 24,417 · Balance 1,450,716 F2: Represents shares surrendered to Euronet Worldwide, Inc. by the Reporting Person to satisfy tax withholding liability obligations associated with the vesting of performance-based restricted stock. |
| Common Stock, par value $0.02 per shareSEC Table I · non-derivative | IndirectBy 401(k) Plan | 5,960 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,960 |
| Common Stock, par value $0.02 per shareSEC Table I · non-derivative | IndirectSee | 211,248 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 211,248 F3: Shares held by Mr. Brown's spouse as custodian for his children. |
| Common Stock, par value $0.02 per shareSEC Table I · non-derivative | IndirectBy Family Trusts | 171,400 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 171,400 F4: Shares held by family trusts for the benefit of Mr. Brown's spouse and children, of which Mr. Brown's spouse is the trustee. |
| Common Stock, par value $0.02 per shareSEC Table I · non-derivative | IndirectBy Spouse | 158,715 |
Reported balance
Holding disclosure · report date 2026-02-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 158,715 |
Filing footnotes · ownership attribution and instrument terms
F1: Vesting of shares from performance-based stock awards granted on December 7, 2021 (3,935), December 6, 2022 (40,345), December 12, 2023 (5,675) and December 10, 2024 (4,994).
F2: Represents shares surrendered to Euronet Worldwide, Inc. by the Reporting Person to satisfy tax withholding liability obligations associated with the vesting of performance-based restricted stock.
F3: Shares held by Mr. Brown's spouse as custodian for his children.
F4: Shares held by family trusts for the benefit of Mr. Brown's spouse and children, of which Mr. Brown's spouse is the trustee.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Monopar Therapeutics
Report date September 24, 2025 · Filed September 26, 2025
Jointly reported with Tactic Pharma LLC, Robinson Chandler, O'Halloran Thomas V., Mazar Andrew Paul
Section 16 reporting ended · disclosed 2025-09-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 272,026 |
Reported balance
After 2025-09-24 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-09-24 · Sale · Disposed 550,229 · Balance 272,026 F1: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. The Reporting Persons are no longer subject to Section 16, except for Chandler D. Robinson, who serves as Chief Executive Officer of Monopar Therapeutics Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2022 Filed Nov 22, 2022 22:26 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | SaleCommon Stock, par value $0.02 per share | 15,689 | $89.87 | $1,409,970.43 |
DisclosureSEC source: 0001213900-22-074641 · ownership.xml · nonDerivative · entry 2 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,467,763 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.50 to $90.16, inclusive. The Reporting Person undertakes to provide to Euronet Worldwide, Inc., any security holder of Euronet Worldwide, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range referred herein. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 22:26 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | Exercise / conversionCommon Stock, par value $0.02 per share | 25,000 | $23.63 | $590,750.00 |
DisclosureSEC source: 0001213900-22-074641 · ownership.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,483,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 19:41 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-013277 · section16.xml · derivative · entry 4 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,859 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2022 Filed Oct 3, 2022 19:41 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-013277 · section16.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 16:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-009146 · section16.xml · derivative · entry 4 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,718 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 16:15 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-009146 · section16.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| May 12, 2022 Filed May 16, 2022 21:16 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | SaleCommon Stock, par value $0.02 per share | 10,000 | $111.11 | $1,111,100.00 |
DisclosureSEC source: 0001213900-22-027240 · ownership.xml · nonDerivative · entry 5 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 24,000 F1 · price: This price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.04 to $111.47, inclusive. The Reporting Person undertakes to provide Euronet Worldwide, Inc., any security holder of Euronet Worldwide, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range referred herein. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 17:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 2,859 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-004478 · section16.xml · derivative · entry 4 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,577 Underlying: Common Stock · 2,859 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On February 2, 2022 the reporting person was granted 11,436 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2022 Filed Apr 1, 2022 17:02 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 2,859 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-004478 · section16.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 21:14 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | GrantCommon Stock, par value $0.02 per share | 5,629 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-009211 · ownership.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,458,752 F1 · kind: Vesting of shares from performance-based restricted stock awards granted on December 13, 2016 (1,627), December 12, 2017 (1,305), December 12, 2018 (1,077), December 10, 2019 (1,620). Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 19:34 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 11,436 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-001170 · section16.xml · derivative · entry 2 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,436 Underlying: Common Stock · 11,436 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. Read SEC document |
| February 02, 2022 Filed Feb 4, 2022 19:34 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 15,128 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001654954-22-001170 · section16.xml · derivative · entry 1 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,128 Underlying: Common Stock · 15,128 shares Expires 2032-02-01 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2022, June 30, 2022, September 30, 2022 and December 31, 2022. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 13:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-22-000119 · section16.xml · derivative · entry 4 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 13:36 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-22-000119 · section16.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 30, 2021 Filed Feb 14, 2022 21:00 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | GiftCommon Stock, par value $0.02 per share | 250 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-22-007470 · ownership.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,453,123 Read SEC document |
| December 08, 2021 Filed Dec 9, 2021 23:07 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | GrantCommon Stock, par value $0.02 per share | 9,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-064469 · ownership.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,453,373 F1 · kind: Vesting of shares from time-based restricted stock awards granted on December 8, 2020. Read SEC document |
| December 07, 2021 Filed Dec 9, 2021 23:07 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | GrantEmployee Stock Option (right to buy) · Derivative | 113,346 | $116.08 Strike: $116.08 | $13,157,203.68 |
DisclosureSEC source: 0001213900-21-064469 · ownership.xml · derivative · entry 6 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,346 Underlying: Common Stock · 113,346 shares Expires 2031-12-07 F4 · derivative.exercise_date: The award vests 25% per year beginning December 7, 2022, contingent on the Company's share price closing above $127.69 for 30 consecutive days during the four year measurement period. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 13:18 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 100,379 | $16.39 Strike: $16.39 | $1,645,211.81 |
DisclosureSEC source: 0001213900-21-063797 · ownership.xml · derivative · entry 6 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,379 shares Expires 2021-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 13:18 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | Exercise / conversionCommon Stock, par value $0.02 per share | 100,379 | $16.39 | $1,645,211.81 |
DisclosureSEC source: 0001213900-21-063797 · ownership.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,443,589 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:01 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 21,600 | $16.39 Strike: $16.39 | $354,024.00 |
DisclosureSEC source: 0001213900-21-057012 · ownership.xml · derivative · entry 6 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,379 Underlying: Common Stock · 21,600 shares Expires 2021-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 20:01 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | Exercise / conversionCommon Stock, par value $0.02 per share | 21,600 | $16.39 | $354,024.00 |
DisclosureSEC source: 0001213900-21-057012 · ownership.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,343,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 19:22 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-010714 · section16.xml · derivative · entry 4 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 751 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 19:22 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-010714 · section16.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 20:15 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 24,300 | $16.39 Strike: $16.39 | $398,277.00 |
DisclosureSEC source: 0001213900-21-050311 · ownership.xml · derivative · entry 6 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,979 Underlying: Common Stock · 24,300 shares Expires 2021-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 24, 2021 Filed Sep 28, 2021 20:15 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | Exercise / conversionCommon Stock, par value $0.02 per share | 24,300 | $16.39 | $398,277.00 |
DisclosureSEC source: 0001213900-21-050311 · ownership.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,321,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 17:18 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 752 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-007603 · section16.xml · derivative · entry 4 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,502 Underlying: Common Stock · 752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 17:18 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 752 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-007603 · section16.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 19:42 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 751 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-003791 · section16.xml · derivative · entry 4 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,254 Underlying: Common Stock · 751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 26, 2021 the reporting person was granted 3,005 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2021, June 30, 2021, September 30, 2021, and December 31, 2021. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 19:42 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 751 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-003791 · section16.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 22:17 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | Tax withholdingCommon Stock, par value $0.02 per share | 2,249 | $156.27 | $351,451.23 |
DisclosureSEC source: 0001213900-21-011716 · ownership.xml · nonDerivative · entry 2 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,297,310 F2 · kind: Represents shares surrendered to Euronet Worldwide, Inc. by the Reporting Person to satisfy tax withholding liability obligations associated with the vesting of performance-based restricted stock. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 22:17 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | GrantCommon Stock, par value $0.02 per share | 7,236 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-21-011716 · ownership.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,299,559 F1 · kind: Vesting of shares from performance-based restricted stock awards granted on December 10, 2015 (1,606), December 13, 2016 (1,628), December 12, 2017 (1,304), December 12, 2018 (1,077), and December 10, 2019 (1,621). Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 11,929 | $16.90 | $201,600.10 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 5 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,667 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.77 to $17.01, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 16,384 | $16.44 | $269,352.96 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 4 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,596 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.77 to $16.76, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 29,996 | $15.12 | $453,539.52 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 3 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,980 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.76 to $15.75, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 24,224 | $14.09 | $341,316.16 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 2 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,976 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.66 to $14.54, inclusive. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 19:35 UTC | Monopar Therapeutics MNPR · Entity 5152 | SaleCommon stock | 42,467 | $13.30 | $564,811.10 |
DisclosureSEC source: 0001654954-21-001750 · section16.xml · nonDerivative · entry 1 Tactic Pharma LLC · CIK 0001727357 · 10% owner Mazar Andrew Paul · CIK 0001727393 · Director · Chief Scientific Officer Robinson Chandler · CIK 0001727334 · Director · Chief Executive Officer O'Halloran Thomas V. · CIK 0001727481 · 10% owner Brown Michael J · CIK 0001035909 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,200 F1 · date: Trade made pursuant to a 10b5-1 plan executed on November 24, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.66 to $13.65, inclusive. The reporting person undertakes to provide to Monopar Therapeutics Inc., any security holder of Monopar Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4. F2 · ownership.direct: This Form 4 is being filed on behalf of Tactic Pharma LLC, an Illinois limited liability company ("Tactic"), and its managers, Andrew P. Mazar, Chandler D. Robinson, Michael J. Brown, and Thomas V. O'Halloran (collectively, the "Reporting Persons"). The managers collectively have voting control over the securities described herein. The managers each disclaim ownership of the shares of common stock owned by Tactic, except to the extent of their pecuniary interest therein. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 18:56 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantRestricted Stock Units · Derivative | 3,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000919 · section16.xml · derivative · entry 2 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,005 Underlying: Common Stock · 3,005 shares Expires not disclosed F2 · derivative.exercise_date: RSUs vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. F2 · derivative.expiration_date: RSUs vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 18:56 UTC | Monopar Therapeutics MNPR · Entity 5152 | GrantStock Options · Derivative | 4,443 | $0.00 Strike: $6.81 | $0.00 |
DisclosureSEC source: 0001654954-21-000919 · section16.xml · derivative · entry 1 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,443 Underlying: Common Stock · 4,443 shares Expires 2031-01-25 F1 · derivative.exercise_date: Options vest 25% quarterly on March 31, 2021, June 30, 2021, September 30, 2021 and December 31, 2021. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 12:44 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionRestricted Stock Units · Derivative | 322 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-21-000184 · section16.xml · derivative · entry 6 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares acquired on vesting and settlement of restricted stock units. F4 · derivative.exercise_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. F4 · derivative.expiration_date: On January 31, 2020 the reporting person was granted 1,289 restricted stock units, vesting in four equal quarterly installments with vesting dates on March 31, 2020, June 30, 2020, September 30, 2020, and December 31, 2020. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement. Read SEC document |
| December 31, 2020 Filed Jan 6, 2021 12:44 UTC | Monopar Therapeutics MNPR · Entity 5152 | Exercise / conversionCommon Stock | 322 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001654954-21-000184 · section16.xml · nonDerivative · entry 2 Brown Michael J · CIK 0001035909 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares acquired on vesting and settlement of restricted stock units. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 21:00 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $133.22 | $0.00 |
DisclosureSEC source: 0001213900-20-042011 · ownership.xml · derivative · entry 2 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-12-08 F2 · derivative.exercise_date: Up to one third of the shares for this option grant vests upon filing of the 2021 annual report on Form 10-K, and up to two thirds of the shares for this option grant vest upon the earlier of December 8, 2022 or the filing of the 2022 annual report on Form 10-K, and up to 100% of the shares for this option grant vest upon the earlier of December 8, 2023 or the filing of the 2023 annual report on Form 10-K, contingent on the Company achieving certain performance criteria. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 21:00 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | GrantEmployee Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $133.22 | $0.00 |
DisclosureSEC source: 0001213900-20-042011 · ownership.xml · derivative · entry 1 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: One third of the shares for this option grant vests on December 8, 2021 and one third on each anniversary thereafter. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 17:02 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | SaleCommon Stock, par value $0.02 per share | 4,723 | $132.30 | $624,852.90 |
DisclosureSEC source: 0001213900-20-038158 · ownership.xml · nonDerivative · entry 6 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,292,323 F4 · price: This price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $132.08 to $132.73, inclusive. The Reporting Person undertakes to provide Euronet Worldwide, Inc., any security holder of Euronet Worldwide, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range referred herein. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 17:02 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | SaleCommon Stock, par value $0.02 per share | 16,906 | $131.85 | $2,229,056.10 |
DisclosureSEC source: 0001213900-20-038158 · ownership.xml · nonDerivative · entry 5 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,297,046 F3 · price: This price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $131.07 to $132.07, inclusive. The Reporting Person undertakes to provide Euronet Worldwide, Inc., any security holder of Euronet Worldwide, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range referred herein. Read SEC document |
| November 18, 2020 Filed Nov 19, 2020 17:02 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | Exercise / conversionCommon Stock, par value $0.02 per share | 41,909 | $17.05 | $714,548.45 |
DisclosureSEC source: 0001213900-20-038158 · ownership.xml · nonDerivative · entry 4 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,313,952 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:02 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | SaleCommon Stock, par value $0.02 per share | 5,653 | $127.21 | $719,118.13 |
DisclosureSEC source: 0001213900-20-038158 · ownership.xml · nonDerivative · entry 3 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,272,043 F2 · price: This price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.03 to $127.43, inclusive. The Reporting Person undertakes to provide Euronet Worldwide, Inc., any security holder of Euronet Worldwide, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range referred herein. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:02 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | SaleCommon Stock, par value $0.02 per share | 15,080 | $126.60 | $1,909,128.00 |
DisclosureSEC source: 0001213900-20-038158 · ownership.xml · nonDerivative · entry 2 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,277,696 F1 · price: This price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.02 to $127.02, inclusive. The Reporting Person undertakes to provide Euronet Worldwide, Inc., any security holder of Euronet Worldwide, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range referred herein. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 17:02 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | Exercise / conversionCommon Stock, par value $0.02 per share | 40,000 | $17.05 | $682,000.00 |
DisclosureSEC source: 0001213900-20-038158 · ownership.xml · nonDerivative · entry 1 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,292,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 16:53 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | SaleCommon Stock, par value $0.02 per share | 12,258 | $125.87 | $1,542,914.46 |
DisclosureSEC source: 0001213900-20-037590 · ownership.xml · nonDerivative · entry 6 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,252,776 F4 · price: This price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.61 to $126.27, inclusive. The Reporting Person undertakes to provide Euronet Worldwide, Inc., any security holder of Euronet Worldwide, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range referred herein. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 16:53 UTC | EURONET WORLDWIDE, INC. EEFT · Entity 4336 | SaleCommon Stock, par value $0.02 per share | 13,724 | $125.28 | $1,719,342.72 |
DisclosureSEC source: 0001213900-20-037590 · ownership.xml · nonDerivative · entry 5 Brown Michael J · CIK 0001035909 · Director · CEO & President of EWI Inc. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,265,034 F3 · price: This price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.60 to $125.60, inclusive. The Reporting Person undertakes to provide Euronet Worldwide, Inc., any security holder of Euronet Worldwide, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range referred herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.